<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p39" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_39{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_39{left:341px;bottom:30px;}
#t3_39{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_39{left:377px;bottom:30px;}
#t5_39{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_39{left:540px;bottom:30px;}
#t7_39{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_39{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_39{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_39{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_39{left:285px;bottom:827px;letter-spacing:-0.26px;}
#tc_39{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_39{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_39{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_39{left:1105px;bottom:47px;letter-spacing:0.34px;}
#tg_39{left:1121px;bottom:28px;letter-spacing:0.19px;word-spacing:-0.15px;}
#th_39{left:1091px;bottom:85px;letter-spacing:-0.11px;}
#ti_39{left:360px;bottom:778px;letter-spacing:0.39px;word-spacing:-0.23px;}
#tj_39{left:545px;bottom:760px;letter-spacing:0.45px;}
#tk_39{left:35px;bottom:747px;}
#tl_39{left:45px;bottom:741px;letter-spacing:0.1px;word-spacing:0.02px;}
#tm_39{left:35px;bottom:730px;}
#tn_39{left:45px;bottom:724px;letter-spacing:0.13px;}
#to_39{left:45px;bottom:707px;letter-spacing:0.13px;word-spacing:0.01px;}
#tp_39{left:35px;bottom:697px;}
#tq_39{left:45px;bottom:691px;letter-spacing:0.09px;word-spacing:-0.01px;}
#tr_39{left:45px;bottom:674px;letter-spacing:0.13px;}
#ts_39{left:35px;bottom:663px;}
#tt_39{left:45px;bottom:657px;letter-spacing:0.09px;word-spacing:0.03px;}
#tu_39{left:45px;bottom:640px;letter-spacing:0.13px;}
#tv_39{left:35px;bottom:629px;}
#tw_39{left:45px;bottom:623px;letter-spacing:0.12px;word-spacing:0.01px;}
#tx_39{left:35px;bottom:613px;}
#ty_39{left:45px;bottom:607px;letter-spacing:0.09px;word-spacing:0.03px;}
#tz_39{left:45px;bottom:590px;letter-spacing:0.13px;}
#t10_39{left:35px;bottom:579px;}
#t11_39{left:45px;bottom:573px;letter-spacing:0.09px;word-spacing:-0.01px;}
#t12_39{left:45px;bottom:556px;letter-spacing:0.13px;}
#t13_39{left:35px;bottom:545px;}
#t14_39{left:45px;bottom:539px;letter-spacing:0.1px;word-spacing:0.03px;}
#t15_39{left:45px;bottom:523px;letter-spacing:0.11px;word-spacing:0.02px;}
#t16_39{left:35px;bottom:512px;}
#t17_39{left:45px;bottom:506px;letter-spacing:0.13px;}
#t18_39{left:45px;bottom:489px;letter-spacing:0.13px;}
#t19_39{left:35px;bottom:478px;letter-spacing:0.08px;}
#t1a_39{left:52px;bottom:472px;letter-spacing:0.1px;word-spacing:0.01px;}
#t1b_39{left:52px;bottom:455px;letter-spacing:0.12px;word-spacing:0.02px;}
#t1c_39{left:35px;bottom:444px;letter-spacing:-0.83px;}
#t1d_39{left:51px;bottom:439px;letter-spacing:0.13px;}
#t1e_39{left:51px;bottom:422px;letter-spacing:0.13px;}
#t1f_39{left:35px;bottom:411px;letter-spacing:0.08px;}
#t1g_39{left:52px;bottom:405px;letter-spacing:0.1px;word-spacing:-0.03px;}
#t1h_39{left:44px;bottom:388px;letter-spacing:0.12px;}
#t1i_39{left:35px;bottom:377px;letter-spacing:0.08px;}
#t1j_39{left:52px;bottom:371px;letter-spacing:0.1px;word-spacing:0.03px;}
#t1k_39{left:44px;bottom:354px;letter-spacing:0.13px;}
#t1l_39{left:35px;bottom:344px;letter-spacing:0.08px;}
#t1m_39{left:52px;bottom:338px;letter-spacing:0.11px;word-spacing:0.01px;}
#t1n_39{left:44px;bottom:321px;letter-spacing:0.04px;}
#t1o_39{left:35px;bottom:310px;letter-spacing:0.08px;}
#t1p_39{left:52px;bottom:304px;letter-spacing:0.1px;word-spacing:0.01px;}
#t1q_39{left:44px;bottom:287px;letter-spacing:0.13px;word-spacing:-0.11px;}
#t1r_39{left:35px;bottom:276px;letter-spacing:0.08px;}
#t1s_39{left:52px;bottom:270px;letter-spacing:0.09px;}
#t1t_39{left:49px;bottom:254px;letter-spacing:0.13px;}
#t1u_39{left:35px;bottom:243px;letter-spacing:0.08px;}
#t1v_39{left:52px;bottom:237px;letter-spacing:0.1px;}
#t1w_39{left:52px;bottom:220px;letter-spacing:0.1px;word-spacing:0.03px;}
#t1x_39{left:35px;bottom:209px;letter-spacing:0.08px;}
#t1y_39{left:52px;bottom:203px;letter-spacing:0.1px;word-spacing:0.01px;}
#t1z_39{left:44px;bottom:186px;letter-spacing:0.11px;word-spacing:0.04px;}
#t20_39{left:35px;bottom:176px;letter-spacing:0.08px;}
#t21_39{left:52px;bottom:170px;letter-spacing:0.1px;word-spacing:-0.02px;}
#t22_39{left:44px;bottom:153px;letter-spacing:0.09px;word-spacing:-0.04px;}
#t23_39{left:35px;bottom:142px;letter-spacing:0.08px;}
#t24_39{left:52px;bottom:136px;letter-spacing:0.09px;word-spacing:-0.01px;}
#t25_39{left:44px;bottom:119px;letter-spacing:0.13px;}
#t26_39{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_39{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_39{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_39{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_39{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_39{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_39{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_39{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.s7_39{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s8_39{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s9_39{font-size:15px;font-family:ArialMT_k0;color:#000;}
.sa_39{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts39" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

</style>
<div id="pg39Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg39" style="-webkit-user-select: none;"><object width="1210" height="935" data="39/39.svg" type="image/svg+xml" id="pdf39" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_39" class="t s0_39">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_39" class="t s1_39">® </span>
<span id="t3_39" class="t s0_39">(NCCN </span>
<span id="t4_39" class="t s1_39">® </span>
<span id="t5_39" class="t s0_39">), All rights reserved. NCCN Guidelines </span>
<span id="t6_39" class="t s1_39">® </span>
<span id="t7_39" class="t s0_39">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_39" class="t s2_39">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_39" class="t s2_39">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_39" class="t s3_39">NCCN Guidelines Version 4.2024 </span>
<span id="tb_39" class="t s3_39">Cancer of the Nasopharynx </span>
<span id="tc_39" class="t s4_39">NCCN Guidelines Index </span>
<span id="td_39" class="t s4_39">Table of Contents </span>
<span id="te_39" class="t s4_39">Discussion </span>
<span id="tf_39" class="t s5_39">NASO-B </span>
<span id="tg_39" class="t s5_39">2 OF 3 </span>
<span id="th_39" class="t s6_39">Continued </span>
<span id="ti_39" class="t s5_39">SYSTEMIC THERAPY FOR NASOPHARYNGEAL CANCERS </span>
<span id="tj_39" class="t s5_39">REFERENCES </span>
<span id="tk_39" class="t s7_39">1 </span>
<span id="tl_39" class="t s8_39">Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med 2019;381:1124-1135. </span>
<span id="tm_39" class="t s7_39">2 </span>
<span id="tn_39" class="t s8_39">Bae WK, Hwang JE, Shim HJ, et al. Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally </span>
<span id="to_39" class="t s8_39">advanced nasopharyngeal cancer. Cancer Chemother Pharmacol 2010;65:589-595. </span>
<span id="tp_39" class="t s7_39">3 </span>
<span id="tq_39" class="t s8_39">Chen YP, Tang LL, Yang Q, et al. Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled </span>
<span id="tr_39" class="t s9_39">analysis of four randomized trials. Clin Cancer Res 2018;24:1824-1833. </span>
<span id="ts_39" class="t s7_39">4 </span>
<span id="tt_39" class="t s8_39">Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced </span>
<span id="tu_39" class="t s8_39">nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol 2016;17:1509-1520. </span>
<span id="tv_39" class="t s7_39">5 </span>
<span id="tw_39" class="t s8_39">Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-1715. </span>
<span id="tx_39" class="t s7_39">6 </span>
<span id="ty_39" class="t s9_39">Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced </span>
<span id="tz_39" class="t s8_39">nasopharyngeal carcinoma. J Clin Oncol 2009;27:242-249. </span>
<span id="t10_39" class="t s7_39">7 </span>
<span id="t11_39" class="t s8_39">Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced </span>
<span id="t12_39" class="t s8_39">nasopharyngeal carcinoma. J Natl Cancer Inst 2005;97:536-539. </span>
<span id="t13_39" class="t s7_39">8 </span>
<span id="t14_39" class="t s8_39">Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, et al. Systemic therapy/RT comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: </span>
<span id="t15_39" class="t s8_39">randomised, non-inferiority, open trial. Eur J Cancer 2007;43:1399-1406. </span>
<span id="t16_39" class="t s7_39">9 </span>
<span id="t17_39" class="t s9_39">Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup </span>
<span id="t18_39" class="t s8_39">study 0099. J Clin Oncol 1998;16:1310-1317. </span>
<span id="t19_39" class="t s7_39">10 </span>
<span id="t1a_39" class="t s8_39">Dechaphunkul T, Pruegsanusak K, Sangthawan D, Sunpaweravong P. Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5-fluorouracil in </span>
<span id="t1b_39" class="t s8_39">locally advanced nasopharyngeal carcinoma. Head Neck Oncol 2011;3:30. </span>
<span id="t1c_39" class="t s7_39">11 </span>
<span id="t1d_39" class="t s8_39">Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with </span>
<span id="t1e_39" class="t s8_39">locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 2012;13:163-171. </span>
<span id="t1f_39" class="t s7_39">12 </span>
<span id="t1g_39" class="t s8_39">Chen YP, Liu X, Zhou Q, et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, </span>
<span id="t1h_39" class="t s8_39">parallel-group, randomised, controlled, phase 3 trial. Lancet 2021;398:303-313. </span>
<span id="t1i_39" class="t s7_39">13 </span>
<span id="t1j_39" class="t s9_39">Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy </span>
<span id="t1k_39" class="t s8_39">alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22:69-76. </span>
<span id="t1l_39" class="t s7_39">14 </span>
<span id="t1m_39" class="t s8_39">Kong F, Zhou J, Du C, et al. Long-term survival and late complications of intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. BMC Cancer </span>
<span id="t1n_39" class="t s8_39">2018;18:1139. </span>
<span id="t1o_39" class="t s7_39">15 </span>
<span id="t1p_39" class="t s8_39">Lee VHF, Kwong DL, Leung T-W, et al. Hyperfractionation compared to standard fractionation in intensity-modulated radiation therapy for patients with locally </span>
<span id="t1q_39" class="t s8_39">advanced recurrent nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol 2017;274:1067-1078. </span>
<span id="t1r_39" class="t s7_39">16 </span>
<span id="t1s_39" class="t s8_39">Jin Y, Cai XY, Shi YX, et al. Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma. J Cancer </span>
<span id="t1t_39" class="t s8_39">Res Clin Oncol 2012;138:1717-1725. </span>
<span id="t1u_39" class="t s7_39">17 </span>
<span id="t1v_39" class="t s8_39">Hong S, Zhang Y, Yu G, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma: </span>
<span id="t1w_39" class="t s8_39">Final overall survival analysis of GEM20110714 phase III study. J Clin Oncol 2021;39:3273-3282. </span>
<span id="t1x_39" class="t s7_39">18 </span>
<span id="t1y_39" class="t s9_39">Mai HQ, Chen QY, Chen D, et al. Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial. </span>
<span id="t1z_39" class="t s8_39">JAMA 2023;330:1961-1970. </span>
<span id="t20_39" class="t s7_39">19 </span>
<span id="t21_39" class="t s9_39">Yang Y, Qu S, Li J, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal </span>
<span id="t22_39" class="t s8_39">carcinoma (captain-1st): A multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2021;22:1162-1174. </span>
<span id="t23_39" class="t s7_39">20 </span>
<span id="t24_39" class="t s8_39">Mai H-Q, Chen Q-Y, Chen D, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: A multicenter </span>
<span id="t25_39" class="t s9_39">randomized phase 3 trial. Nat Med 2021;27:1536-1543. </span>
<span id="t26_39" class="t sa_39">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
